| Clinical Takeaway |
| Domain | Key Finding | Evidence Level |
| The question | Does evolocumab started in the cath lab, before PCI for an acute MI, get more patients to LDL goal at 1 year than standard stepwise therapy, and does it produce an early clinical benefit? | Open-label RCT, blinded endpoints, n=2,161 |
| The lipid result | 82% vs. 40% met the LDL target at 12 months, with a median LDL of 16 vs. 56 mg/dL at 6 weeks. | RCT primary endpoint, JAMA 2026 |
| The clinical result | Death or unplanned cardiovascular hospitalization at 1 year: 14.6% vs. 15.4% (adjusted OR 0.94; 95% CI 0.73–1.19). Inconclusive: the interval is compatible with a modest benefit, no effect, or modest harm. | Wide confidence interval; 12 months of follow-up |
| Where it fits | Not a reason to slow LDL lowering after an MI. Under guideline stepwise care with 5 study visits, 60% of control patients had not met the combined LDL target at 12 months. | Control-arm RCT data; timing context from CTT and FOURIER |
|
Six weeks after a heart attack, patients who started evolocumab before their procedure had a median LDL of 16 mg/dL. With standard care, it was 56.
That's a large difference. But after a year, the AMUNDSEN trial hadn't shown a statistically significant difference in death or unplanned cardiovascular hospitalization: 14.6% with evolocumab, 15.4% with standard care.
I wouldn't take that as a reason to back off LDL lowering. I would ask how much benefit a study this size could reasonably detect in a year.
